These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 23613845)

  • 1. The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection.
    White MT; Bejon P; Olotu A; Griffin JT; Riley EM; Kester KE; Ockenhouse CF; Ghani AC
    PLoS One; 2013; 8(4):e61395. PubMed ID: 23613845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection.
    Foquet L; Hermsen CC; van Gemert GJ; Van Braeckel E; Weening KE; Sauerwein R; Meuleman P; Leroux-Roels G
    J Clin Invest; 2014 Jan; 124(1):140-4. PubMed ID: 24292709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.
    Sun P; Schwenk R; White K; Stoute JA; Cohen J; Ballou WR; Voss G; Kester KE; Heppner DG; Krzych U
    J Immunol; 2003 Dec; 171(12):6961-7. PubMed ID: 14662904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.
    Lalvani A; Moris P; Voss G; Pathan AA; Kester KE; Brookes R; Lee E; Koutsoukos M; Plebanski M; Delchambre M; Flanagan KL; Carton C; Slaoui M; Van Hoecke C; Ballou WR; Hill AV; Cohen J
    J Infect Dis; 1999 Nov; 180(5):1656-64. PubMed ID: 10515829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D).
    Agnandji ST; Fendel R; Mestré M; Janssens M; Vekemans J; Held J; Gnansounou F; Haertle S; von Glasenapp I; Oyakhirome S; Mewono L; Moris P; Lievens M; Demoitie MA; Dubois PM; Villafana T; Jongert E; Olivier A; Cohen J; Esen M; Kremsner PG; Lell B; Mordmüller B
    PLoS One; 2011 Apr; 6(4):e18559. PubMed ID: 21494604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
    Kester KE; Cummings JF; Ofori-Anyinam O; Ockenhouse CF; Krzych U; Moris P; Schwenk R; Nielsen RA; Debebe Z; Pinelis E; Juompan L; Williams J; Dowler M; Stewart VA; Wirtz RA; Dubois MC; Lievens M; Cohen J; Ballou WR; Heppner DG;
    J Infect Dis; 2009 Aug; 200(3):337-46. PubMed ID: 19569965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irradiated sporozoite vaccination induces sex-specific immune responses and protection against malaria in mice.
    Vom Steeg LG; Flores-Garcia Y; Zavala F; Klein SL
    Vaccine; 2019 Jul; 37(32):4468-4476. PubMed ID: 31262583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines.
    White MT; Griffin JT; Riley EM; Drakeley CJ; Moorman AM; Sumba PO; Kazura JW; Ghani AC; John CC
    Proc Biol Sci; 2011 May; 278(1710):1298-305. PubMed ID: 20943696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E.
    Ndungu FM; Mwacharo J; Kimani D; Kai O; Moris P; Jongert E; Vekemans J; Olotu A; Bejon P
    PLoS One; 2012; 7(12):e52870. PubMed ID: 23300801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.
    Bojang KA; Milligan PJ; Pinder M; Vigneron L; Alloueche A; Kester KE; Ballou WR; Conway DJ; Reece WH; Gothard P; Yamuah L; Delchambre M; Voss G; Greenwood BM; Hill A; McAdam KP; Tornieporth N; Cohen JD; Doherty T;
    Lancet; 2001 Dec; 358(9297):1927-34. PubMed ID: 11747915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systems analysis of protective immune responses to RTS,S malaria vaccination in humans.
    Kazmin D; Nakaya HI; Lee EK; Johnson MJ; van der Most R; van den Berg RA; Ballou WR; Jongert E; Wille-Reece U; Ockenhouse C; Aderem A; Zak DE; Sadoff J; Hendriks J; Wrammert J; Ahmed R; Pulendran B
    Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2425-2430. PubMed ID: 28193898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: a case-control study.
    Dobaño C; Ubillos I; Jairoce C; Gyan B; Vidal M; Jiménez A; Santano R; Dosoo D; Nhabomba AJ; Ayestaran A; Aguilar R; Williams NA; Díez-Padrisa N; Lanar D; Chauhan V; Chitnis C; Dutta S; Gaur D; Angov E; Asante KP; Owusu-Agyei S; Valim C; Gamain B; Coppel RL; Cavanagh D; Beeson JG; Campo JJ; Moncunill G
    BMC Med; 2019 Aug; 17(1):157. PubMed ID: 31409398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.
    White MT; Verity R; Griffin JT; Asante KP; Owusu-Agyei S; Greenwood B; Drakeley C; Gesase S; Lusingu J; Ansong D; Adjei S; Agbenyega T; Ogutu B; Otieno L; Otieno W; Agnandji ST; Lell B; Kremsner P; Hoffman I; Martinson F; Kamthunzu P; Tinto H; Valea I; Sorgho H; Oneko M; Otieno K; Hamel MJ; Salim N; Mtoro A; Abdulla S; Aide P; Sacarlal J; Aponte JJ; Njuguna P; Marsh K; Bejon P; Riley EM; Ghani AC
    Lancet Infect Dis; 2015 Dec; 15(12):1450-8. PubMed ID: 26342424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates.
    Tewari K; Flynn BJ; Boscardin SB; Kastenmueller K; Salazar AM; Anderson CA; Soundarapandian V; Ahumada A; Keler T; Hoffman SL; Nussenzweig MC; Steinman RM; Seder RA
    Vaccine; 2010 Oct; 28(45):7256-66. PubMed ID: 20846528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine.
    Moris P; Jongert E; van der Most RG
    Hum Vaccin Immunother; 2018 Jan; 14(1):17-27. PubMed ID: 28934066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of
    Kurtovic L; Wetzel D; Reiling L; Drew DR; Palmer C; Kouskousis B; Hanssen E; Wines BD; Hogarth PM; Suckow M; Jenzelewski V; Piontek M; Chan JA; Beeson JG
    Front Immunol; 2021; 12():641421. PubMed ID: 33815393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine.
    Kaba SA; McCoy ME; Doll TA; Brando C; Guo Q; Dasgupta D; Yang Y; Mittelholzer C; Spaccapelo R; Crisanti A; Burkhard P; Lanar DE
    PLoS One; 2012; 7(10):e48304. PubMed ID: 23144750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
    Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG
    Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategic Variants of CSP Delivered as SynDNA Vaccines Demonstrate Heterogeneity of Immunogenicity and Protection from
    Reeder SM; Bah MA; Tursi NJ; Brooks RC; Patel A; Esquivel R; Eaton A; Jhun H; Chu J; Kim K; Xu Z; Zavala F; Weiner DB
    Infect Immun; 2021 Sep; 89(10):e0072820. PubMed ID: 34152830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.